Teva Pharmaceutical Industries Ltd.'s acquisition of ratiopharm Group, the German generics company, announced March 18, could hardly have been a surprise for anyone following the Israeli company's recent rip-roaring endorsement of the opportunities in the European generics market and the German market in particular. [See Deal]
The purchase of the privately held ratiopharm Group solidifies Teva's number one position in the European generics industry and fits...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?